Oppenheimer Asset Management Inc. boosted its stake in shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) by 251.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,862 shares of the biopharmaceutical company’s stock after purchasing an additional 2,047 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Portola Pharmaceuticals were worth $155,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Portola Pharmaceuticals by 14.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,078 shares of the biopharmaceutical company’s stock worth $117,000 after acquiring an additional 258 shares in the last quarter. Jacobi Capital Management LLC acquired a new stake in shares of Portola Pharmaceuticals in the second quarter worth $125,000. IFP Advisors Inc increased its position in shares of Portola Pharmaceuticals by 7.7% in the second quarter. IFP Advisors Inc now owns 2,370 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 170 shares in the last quarter. QS Investors LLC acquired a new stake in shares of Portola Pharmaceuticals in the second quarter worth $147,000. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Portola Pharmaceuticals in the third quarter worth $178,000. 87.45% of the stock is currently owned by institutional investors.

Several equities research analysts have recently issued reports on the stock. Goldman Sachs Group assumed coverage on shares of Portola Pharmaceuticals in a research report on Friday, December 1st. They issued a “buy” rating and a $75.00 price objective for the company. Morgan Stanley reissued an “overweight” rating and issued a $81.00 price objective (up previously from $75.00) on shares of Portola Pharmaceuticals in a research report on Friday, October 6th. Credit Suisse Group raised shares of Portola Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $70.00 price objective for the company in a research report on Wednesday, August 23rd. Oppenheimer set a $80.00 price objective on shares of Portola Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, December 13th. Finally, BidaskClub raised shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 25th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $71.15.

In related news, Director Henry Ward Wolff sold 12,000 shares of the firm’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $47.00, for a total transaction of $564,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 5.50% of the stock is currently owned by company insiders.

Shares of Portola Pharmaceuticals Inc (PTLA) opened at $47.60 on Tuesday. Portola Pharmaceuticals Inc has a fifty-two week low of $18.63 and a fifty-two week high of $67.10. The company has a debt-to-equity ratio of 0.24, a current ratio of 8.31 and a quick ratio of 8.31.

Portola Pharmaceuticals (NASDAQ:PTLA) last released its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.49) by $0.08. The business had revenue of $3.83 million during the quarter, compared to analyst estimates of $4.71 million. Portola Pharmaceuticals had a negative net margin of 938.19% and a negative return on equity of 110.46%. The business’s revenue was down 58.9% on a year-over-year basis. During the same period last year, the business earned ($1.64) EPS. research analysts expect that Portola Pharmaceuticals Inc will post -4.94 earnings per share for the current fiscal year.

WARNING: “Portola Pharmaceuticals Inc (PTLA) Holdings Boosted by Oppenheimer Asset Management Inc.” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/portola-pharmaceuticals-inc-ptla-holdings-boosted-by-oppenheimer-asset-management-inc/1772400.html.

Portola Pharmaceuticals Profile

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Institutional Ownership by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.